+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

P

Actively Recruiting

This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.

Age: 18Years - 68YearsAll GendersPhase 2
79 locations
C

Actively Recruiting

Researchers are evaluating the combination of Surovatamig AZD0486 and rituximab for treating participants with previously untreated follicular lymphoma. This global, randomized, open-label Phase III study aims to compare the efficacy, safety, and added benefit of this combination versus three standard immunochemotherapy regimens chosen by the investigator. The study includes a safety run-in phase to determine the recommended dose followed by the main Phase III comparison. The study has two parts first, a safety run-in to compare different dose levels of Surovatamig combined with rituximab to establish the recommended Phase III dose RP3D. Then, the Phase III part, which compares three treatment arms two with different Surovatamig plus rituximab schedules and one with investigators choice of standard chemoimmunotherapy regimens R-CVP, R-CHOP, or B-R followed by rituximab maintenance. Participants are randomly assigned to one of these arms. During the study, participants undergo safety monitoring, including tracking of adverse events and treatment tolerability, for up to 10 years. Researchers assess treatment response, progression, and survival outcomes over this period. Participants receive regular evaluations of disease status, organ function, and overall health. The study aims to measure safety, the best dose, and whether Surovatamig plus rituximab is superior to standard treatments in this patient group.

Age: 18Years - 130YearsAll GendersPhase 3
244 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
R

Actively Recruiting

Researchers are evaluating VIA Disc NP, a non-surgical treatment designed to supplement the nucleus pulposus tissue in degenerated intervertebral discs. This randomized, sham-controlled, multi-center, double-blind clinical trial includes participants with lumbar discogenic pain related to degenerative disc disease DDD. The study aims to assess the safety and effectiveness of this treatment for managing moderate to severe disc-related back pain. Participants will receive one VIA Disc NP treatment injected into each affected disc level, with up to two levels treated per person. After an initial open-label roll-in period, participants are randomized in a 21 ratio to receive either the VIA Disc NP injection or a sham procedure that mimics the treatment without injecting any material. Participants in the sham group who still have symptoms after 12 months may cross over to receive the VIA Disc NP treatment and continue follow-up for another 12 months. During the study, participants will be closely monitored through scheduled visits to evaluate pain reduction using the Visual Analog Scale VAS and to record any treatment-related adverse events over 12 months. The main outcomes include the proportion of participants achieving meaningful pain improvement and the frequency of adverse events related to the treatment. Follow-up assessments and monitoring will continue throughout the study duration, which extends up to the study completion date in October 2028.

Age: 22Years - 85YearsAll GendersPhase Not Applicable
19 locations
C

Actively Recruiting

Researchers are conducting a randomized, open-label phase 3 clinical trial to compare treatments for adults with advanced or metastatic non-small cell lung cancer NSCLC who have developed resistance to immune checkpoint inhibitor therapy. The study focuses on two groups one receiving N-803 plus tislelizumab and docetaxel, and the other having previously failed immune checkpoint inhibitor therapy combined with docetaxel. The trial aims to evaluate the effectiveness and safety of these treatments compared to docetaxel alone. Participants are assigned to two cohorts and randomized in a 21 ratio to either the experimental treatment or control arm. Cohort A receives N-803, tislelizumab, and docetaxel during the first two 3-week cycles, followed by N-803 and tislelizumab until the study ends. Cohort B receives N-803, their prior failed checkpoint inhibitor, and docetaxel in the first two cycles, then N-803 and the prior checkpoint inhibitor thereafter. Control arms for both cohorts receive docetaxel monotherapy in repeated 3-week cycles. During the study, participants undergo treatment cycles every three weeks with scheduled administration of drugs via subcutaneous injection or intravenous infusion. Researchers will assess overall survival approximately 12 months after treatment begins. Participants must attend study visits and follow-ups as required. Safety and treatment effects will be monitored throughout the trial, which is expected to continue until January 2029.

Age: 18Years - 90YearsAll GendersPhase 3
49 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the LINQ fusion procedure compared to conventional medical management for people with sacroiliac joint dysfunction. This randomized, open-label clinical study aims to assess improvements in pain and disability over a 6-month primary period, with longer follow-up to understand ongoing outcomes. Participants are adults aged 21 and older who have chronic sacroiliac joint pain that has not responded well to prior non-surgical treatments. Participants are randomly assigned in a 21 ratio to either receive the minimally invasive LINQ fusion procedure involving bone allograft implantation or to undergo standardized, stepwise non-surgical management known as conventional medical management CMM. After completing 6 months of follow-up, those initially in the CMM group may choose to cross over to receive the LINQ procedure and continue follow-up for 18 months following that procedure. The study includes screening, baseline procedures, randomization, and follow-up visits through 24 months. Throughout the study, participants attend regular visits to monitor pain levels using scales like the Visual Analog Scale VAS and disability through the Oswestry Disability Index ODI, along with quality of life questionnaires and medication use tracking. Safety is closely monitored by recording adverse events at multiple time points up to 24 months. The main outcome focuses on success rates at 6 months, with continued assessments over the longer term to understand treatment effects and patient-reported changes.

Age: 21Years +All GendersPhase 4
1 location
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the Shield blood tests performance for colorectal cancer CRC screening in people aged 45 to 81 who are at average risk for CRC. The study focuses on assessing the test during a second round of screening, using colonoscopy as the reference standard. CRC is a common and serious disease, especially affecting older adults and certain minority groups, with early detection being key to improving outcomes. Participants will undergo the Shield blood test as part of their routine standard care, and their results will be compared to colonoscopy findings. This study is observational and collects real-world evidence over a period of 33 to 42 months after enrollment to assess how well the Shield test performs in detecting CRC or its precursors during the second screening interval. Participants will be involved in scheduled study procedures and standard care assessments, with data collected on the tests accuracy and effectiveness over time. The main outcome measured is the performance of the Shield test during the second testing period. The study will continue until December 2030, monitoring participants to gather long-term information about CRC screening efficacy in an average-risk population.

Age: 45Years - 81YearsAll Genders
69 locations
A

Actively Recruiting

Crohns disease and Ulcerative Colitis are types of inflammatory bowel diseases that cause long-lasting, severe inflammation in the digestive tract. Crohns disease can affect any part of the digestive tract causing symptoms like belly pain, diarrhea, tiredness, and weight loss, while Ulcerative Colitis affects the lining of the rectum and colon causing bleeding, belly pain, and diarrhea. This Phase 2 platform basket study is evaluating the safety and effectiveness of advanced therapies in adults with moderately to severely active Crohns Disease or Ulcerative Colitis. The study includes two substudies focusing on different treatment combinations for participants with Crohns Disease or Ulcerative Colitis. Substudy 1 evaluates the combination of risankizumab and trosunilimab ABBV-466, while Substudy 2 evaluates risankizumab combined with ABBV-701 ABBV-7066. Participants will be randomly assigned first to a substudy and then to a treatment arm within that substudy. Treatments involve induction and maintenance doses of risankizumab, trosunilimab, ABBV-701, or their combinations, given via injection or infusion. Participants will attend regular visits at hospitals or clinics for medical assessments including blood and stool tests, endoscopies, monitoring for side effects, and completing questionnaires and daily diaries. The study measures include the percentage of participants achieving endoscopic remission at Week 28 and the number of participants experiencing adverse events up to 98 weeks. Secondary outcomes include clinical remission and response rates at Weeks 12 and 28. The study will monitor participants for up to 98 weeks from the start of treatment.

Age: 18Years - 75YearsAll GendersPhase 2
66 locations